MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (mnc pharma)
- GSK PHARMA
GSK PHARMA Share Price 
(GLXO)
Here is the latest stock price and chart of GSK Pharma. For more details, see the GSK Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
| Live BSE Quotes | Dec 17, 2018 01:31:00 PM | ||
|---|---|---|---|
| Price (Rs)1,388.90 | Open (Rs) 1,383.05 | High (Rs) 1,388.90 | Low (Rs) 1,381.90 |
| % Change0.42 | Volume 2,766 | Value (Rs) 3,841,697 | 52-Week H/L 1,812.00 / 1,020.00 |
| Live NSE Quotes | Dec 17, 2018 1:34:59 PM | ||
|---|---|---|---|
| Price (Rs)1,389.85 | Open (Rs) 1,381.20 | High (Rs) 1,390.55 | Low (Rs) 1,377.55 |
| % Change0.40 | Volume 7,688 | Value (Rs) 10,652,262 | 52-Week H/L 1,800.05 / 1,010.00 |
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 22.70 | P/E Ratio (x) 61.18 | Market Cap (Rs m) 235,287.99 | P/BV (x) 11.44 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX
PERIOD - Advanced Charts new
- Charts by TradingView
GSK PHARMA Share Price Today:
GSK PHARMA share price is up 0.4% to Rs 1,388.9 on the BSE. On the NSE, the GSK PHARMA share price is up 0.4% to Rs 1,389.9. The total volume of shares traded is 0.0 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading up by 0.3%. And the benchmark S&P BSE SENSEX is at 36,215.4 (up 0.7%).
Over the last 30 days, the GSK PHARMA share price is up 1.9%. And over the last one year, GSK PHARMA share price is up 15.9%.
|
| |
Today's Market
Sensex Trades Over 250 Points Up; Tata Motors & Power Grid Top Gainers(12:30 pm)
Stock markets in India are presently trading higher. The BSE Sensex is trading higher by 252 points and the NSE Nifty is trading higher by 59 points.
Related Views On News
GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)
Oct 23, 2018 | Updated on Oct 23, 2018For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)
Jul 26, 2018 | Updated on Jul 26, 2018For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Shalby Ltd. (IPO)
Dec 2, 2017Should you subscribe to the IPO of Shalby Ltd?
The Power of 5 Minutes (The 5 Minute Wrapup)
Jun 16, 2017Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
More Views on NewsMost Popular
It's Almost the Perfect Time to Buy This Safe Stock(The 5 Minute Wrapup)
Dec 6, 2018My latest StockSelect recommendation ticks all the boxes of a great safe stock.
Patel's Exit, Election Results, and 4 'Must Have' Small Caps in These Exceptional Times(Profit Hunter)
Dec 11, 2018RBI Governor's resignation is a statement of dissent with the way government is handling the economy's affairs and could lead to some serious market correction. Here's how to make the most of it.
Players in an Oligopoly Should Have Financials Like This(Chart Of The Day)
Dec 7, 2018This stock has corrected 30% from peak and looks attractive at these valuations.
Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)
Dec 5, 2018Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.
DSP Mutual Fund's Sale of DHFL Bonds: Here's What You Need to Know(Outside View)
Dec 5, 2018PersonalFN explains the probable reason as to why the capital market regulator has initiated DSP Mutual Fund's bond sale that caused DHFL stock to crash.
MoreTRACK GSK PHARMA
- Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GSK PHARMA
GSK PHARMA - MYLAN COMPARISON
COMPARE GSK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
|
| |
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
FOLLOW
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.